BridgeBio Oncology Therapeutics (BBOT) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

BridgeBio Oncology Therapeutics

NasdaqGM•Healthcare•Biotechnology

$4.95-0.57(-0.10%)Pre-market

Market Cap

$391.46M

P/B

1.2x

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

How this company scores

WeakMetricSide Score: 22/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (1/25).

Profitability2/25

Growth1/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality4/25

Strengths

Interest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 42.6x5y range 24.0x – 42.6x

P/S · 599.4x5y range 599.4x – 106898.1x

Currently below its 6-quarter median.

P/B · 1.2x5y range 0.0x – 1.2x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $391.46M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-247.44M
TTM Op. Income: $-248.64M
Q. Op. Income: $-60.19M
TTM Net Income: $-233.03M
Q. Net Income: $-56.45M
EPS: $-705.2
Shares Out.: $80.05M

$0 in TTM revenue declined 100.0% YoY, reaching $0 last quarter. TTM EBITDA of $-247.44M and TTM operating income of $-248.64M show growth is flowing through to the bottom line. However, net income is negative at $233.03M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 4 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -6018700000.0%
Net Margin: -5645400000.0%

Op. margin of -6018700000.0% is down 6018603205.5% YoY — costs are rising relative to revenue. Net margin at -5645400000.0% Over the past year, operating margin is down 6217920% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 1.2x

P/S of 0.0x and P/B of 1.2x. Across the last 3 quarters, P/E has risen for 2 consecutive quarters — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $376.71M
Cash: $54.06M
Long-Term Debt: N/A
Book Value: $323.11M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-44.36M
TTM Free Cash Flow: $-193.82M
FCF Margin: N/A
FCF / Net Income: 0.8

TTM FCF of $-193.82M on $-44.36M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 7 consecutive quarters — a weakening trend.